Arformoterol
- Atc Codes:R03AC
- CAS Codes:200815-49-2#67346-49-0
- PHARMGKB ID:200815-49-2#67346-49-0
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Substrate of
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
North America
USA: Brovana.
Drug combinations
Chemistry
Arformoterol Tartrate: C~19~H~24~N~2~O~4~ C~4~H~6~O~6~. Mw: 494.49. [Arformoterol is INN.] (1) Formamide, N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, (2R,3R)-2,3-dihydroxybutanedioate (1:1); (2)(-)-N-[2-Hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]formamide hydrogen (2R,3R)-2,3-dihydroxybutanedioate. CAS-200815-49-2; CAS-67346-49-0 (arformoterol)(2003).
Pharmacologic Category
Sympathomimetic (Adrenergic) Agents; Selective β~2~-Adrenergic Agonists. (ATC-Code: R03AC).
Mechanism of action
Relaxes bronchial smooth muscle by selective action on β~2~-receptors.
Therapeutic use
Bronchoconstriction in chronic obstructive pulmonary disease, chronic bronchitis and emphysema.
Pregnancy and lactiation implications
β-agonists may interfere with uterine contractility during labor. Use during pregnancy only if clearly needed. Use with caution during lactation.
Unlabeled use
Contraindications
Hypersensitivity to arformoterol, racemic formoterol, or any component of the formulation.
Warnings and precautions
May increase risk of asthma-related deaths. Bronchospasm might occur. Immediate hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm) may develop. Use with caution in cardiovascular disease (β-agonists may cause elevation in blood pressure, heart rate and may also increase risk of arrhythmias and prolong QTc interval), diabetes mellitus (β~2~-agonists may increase serum glucose), hepatic impairment (prolonged systemic clearance), hyperthyroidism (may stimulate thyroid activity), hypokalemia (β~2~-agonists may decrease serum potassium), or in seizure disorders (β~2~-agonists may result in CNS stimulation/excitation). Should not be initiated in patients with acutely deteriorating chronic obstructive pulmonary disease or combined with other long-acting β~2~-agonists.